CC-99712 + BMS-986405

**CC-99712 + BMS-986405** is an investigational combination therapy studied in patients with relapsed and refractory multiple myeloma. - **CC-99712** is a BCMA (B-cell maturation antigen) antibody-drug conjugate (ADC) that selectively targets and kills BCMA-expressing malignant plasma cells via delivery of a cytotoxic payload[1][5][7]. - **BMS-986405** is a small molecule gamma-secretase inhibitor (GSI); by blocking gamma-secretase, BMS-986405 reduces the cleavage and shedding of BCMA from myeloma cells, thereby increasing cell-surface BCMA and boosting the efficacy of BCMA-directed therapies like CC-99712[10]. - This combination is being tested via intravenous administration for safety, tolerability, and preliminary efficacy in phase 1 clinical trials[1][3][7]. - Developed for use in hematological malignancies, particularly multiple myeloma, especially in those who relapsed or are refractory to standard therapies[1][3][7].

Other names

CC-99712CC99712CC 99712BMS-986405BMS986405BMS 986405